CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease

Open access
Fan, Hui, Pan, QingRong, Xu, Yuan, Yang, XinChun · 2013 · Arquivos Brasileiros de Endocrinologia & Metabologia

Abstract

OBJECTIVE: To investigate the effects of exenatide on blood glucose, body weight and hepatic enzymes in patients with type 2 diabetes mellitus (T2DM) and concomitant non-alcoholic fatty liver disease (NAFLD). SUBJECTS AND METHODS: One hundred and seventeen patients with T2DM and NAFLD were randomly divided into exenatide group and metformin group. Patients were treated with exenatide and metformin, respectively, for 12 weeks. RESULTS: After 12 weeks of treatment, body weight, body mass index (BMI), waist-to-hip ratio, HbA1c, FPG, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were significantly reduced, and the AST/ALT ratio and adiponectin were markedly increased in both groups. BMI, waist-to-hip ratio, 2-h PPG, ALT, AST, γ-GT, and hs-CRP were markedly lower, and AST/ALT ratio and adiponectin in the exenatide group were dramatically higher than in the metformin group. CONCLUSION: Compared with metformin, exenatide is better to control blood glucose, reduces body weight and improves hepatic enzymes, attenuating NAFLD in patients with T2DM concomitant with NAFLD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1590/s0004-27302013000900005

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 124

Metadata

Authors
Fan, H., Pan, Q., Xu, Y., & Yang, X.
Affiliations
Capital Medical University (CN)
Venue
Arquivos Brasileiros de Endocrinologia & Metabologia
Published
2013-12
Volume
57
Issue
9
Pages
702-708
ISSN
0004-2730 (ISSN-L)
OpenAlex
W1969489686
Cited by
122
References
26
Citations by year
2026: 11 · 2025: 9 · 2024: 5 · 2023: 14 · 2022: 12 · 2021: 20 · 2020: 20 · 2019: 6 · 2018: 7 · 2017: 6 · 2016: 4 · 2015: 3 · 2014: 5
FWCI
3.15
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Arquivos Brasileiros de Endocrinologia & Metabologia (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion, other-oa)
  • Americanae (AECID Library) (submittedVersion, other-oa)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
exenatide, type 2 diabetes, non-alcoholic fatty liver disease, metformin, glycemic control, weight loss, liver enzymes, AST/ALT ratio, adiponectin, C-reactive protein, blood glucose
MeSH terms
Exenatide, Adult, Aged, Alanine Transaminase, Blood Glucose, Body Weight, C-Reactive Protein, Diabetes Mellitus, Type 2, Fatty Liver, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides, Time Factors, Venoms, Body Mass Index, Treatment Outcome, Waist-Hip Ratio, Adiponectin, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. https://app.cochat.ai/papers/10.1590/s0004-27302013000900005
The paper
Fan, H., Pan, Q., Xu, Y., & Yang, X. (2013). Exenatide improves type 2 diabetes concomitant with non-alcoholic fatty liver disease. Arquivos Brasileiros de Endocrinologia & Metabologia. https://doi.org/10.1590/s0004-27302013000900005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.